Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Apr 30;50(2):280-3.
doi: 10.3349/ymj.2009.50.2.280.

A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue

Sung Jin Hong  1 , Jin Seok Kim, Jong Hee Chang, Kyoung Min Kim, Soo Jeong Kim, Hye Won Lee, June-Won Cheong, Seung Tae Lee, Yoo Hong Min
Affiliations
Case Reports

A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue

Sung Jin Hong et al. Yonsei Med J. .

Abstract

The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy.

Keywords: Primary central nervous system lymphoma; high-dose chemotherapy with autologous stem cell rescue; rituximab; salvage therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Gadolinium-enhanced, T1-weighted, MRI shows an enhancing lesion involving the right thalamus and splenium of the corpus callosum at relapse.
Fig. 2
Fig. 2
About 50% reduction of the lesion size in the right thalamus after treatment of intraventricular rituximab.
Fig. 3
Fig. 3
Full regression of lymphoma infiltration after 2 cycles of VIA chemotherapy and high-dose chemotherapy with autologous stem-cell rescue.
See this image and copyright information in PMC

References

    1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281–1288. - PubMed
    1. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol. 2000;11:927–937. - PubMed
    1. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58:1513–1520. - PubMed
    1. Reni M, Ferreri AJ. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol. 2001;80(Suppl 3):B113–B117. - PubMed
    1. Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer. 1999;79:530–534. - PMC - PubMed

Publication types

MeSH terms